GlassScriptPhysician profile
David Donahue
NPI 1871589028
$7,862.66
in general payments reported to CMS, 2019-2025
28 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $342 · 2021: $140 · 2022: $1,341 · 2023: $1,102 · 2024: $1,845 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,228 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.98 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.67 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $785.55 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $687.65 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $580.51 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $478.52 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $454.53 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $427.08 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $377.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $353.74 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $351.80 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $319.36 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $313.11 | 2019-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $305.17 | 2019-2025 | Rexulti |
| Allergan, INC. | $263.13 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $242.24 | 2019-2025 | Fanapt, Hetlioz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $220.00 | 2024-2025 | Xelstrym |
| Corium, LLC | $204.47 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $172.78 | 2022-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $104.07 | 2022-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $74.86 | 2022-2023 | Belsomra |
| Shire North American Group INC | $65.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.88 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $29.37 | 2025 | Qelbree |
| Aytu Biopharma, INC. | $27.39 | 2019 | |
| Neos Therapeutics, LP | $17.21 | 2024 | Adzenys Xr-Odt |
| Tonix Medicines, INC. | $16.09 | 2025 | Tonmya |
| Ironshore Pharmaceuticals INC. | $15.73 | 2022 | |
| Alfasigma USA, INC. | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Donahue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.